Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studiesThis Plain Language Summary of Publication article from Neurodegenerative Disease Management looks at the long-term effectiveness of treatment with cladribine tablets in people living with multiple sclerosis.

Read the article here.

The original article on which this summary is based is called ‘Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study’. It was published in Multiple Sclerosis Journal. 

Read the original article here.